IDEXX dominates veterinary diagnostics with a recurring consumables model tied to companion animal health spending. US vet visit growth has slowed post-pandemic, but international expansion and new product innovation (Cancer Dx, Inflammation panel) support the long-term thesis. Pricing power remains durable. Re-rating awaits US vet visit reacceleration.
Thesis reviewed May 29, 2026
IDEXX Laboratories Inc. is headquartered in United States, which is currently showing moderate signals.
πΊπΈUnited States69REDUCEView United States risk detail βπ₯Healthcare28NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| SYK | Stryker Corporation | 32 | +15% | β3% | EARLY |
| UNH | UnitedHealth Group Inc. | 32 | +16% | β3% | AVOID |
| TEVA | Teva Pharmaceutical Industries Ltd. | 32 | +9% | β3% | NEUTRAL |
| ELV | Elevance Health Inc. | 32 | +7% | β3% | NEUTRAL |
| CVS | CVS Health Corporation | 32 | +15% | β3% | AVOID |
| DHR | Danaher Corporation | 32 | +11% | β3% | EARLY |
| TMO | Thermo Fisher Scientific Inc. | 32 | +11% | β3% | EARLY |
Investors who hold IDXX may also have indirect exposure through these country funds.
IDEXX Cancer Dx panel launches in US market
US vet visit volumes stabilize after multi-quarter declines
Estimates Β· Yahoo Finance Β· Not audited figures
| Politician | Party | Type | Amount | Trade Date | Return |
|---|---|---|---|---|---|
| April McClain DelaneyMD | D | Buy | $1kβ$15k | Jan 13, 26 | -11.9% |
| April McClain DelaneyMD | D | Buy | $1kβ$15k | Dec 2, 25 | -17.4% |